Cleveland BioLabs Announces Start of Colorectal Cancer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation

BUFFALO, NY--(Marketwired - Feb 2, 2016) - Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer who are recommended for surgery. 

The primary objective of the study is to determine the optimal dose and dosing regimen for treatment of these patients with entolimod prior to surgery. Secondary objectives include evaluation of pharmacodynamic parameters, including immune response to single or double administrations of entolimod at varying dose levels. Up to 32 patients are expected to be enrolled in the study, which is being conducted at four leading oncology centers in the Russian Federation. The study is supported by a development contract with the Russian Federation Ministry of Industry and Trade.

Langdon Miller, M.D., President and Chief Medical Officer of CBLI, commented, "Preclinical evidence of entolimod's ability to suppress growth of tumors in the liver through mobilization and activation of innate and adaptive immune mechanisms supports investigation of its use in this clinical setting, since the liver is a common site of colorectal cancer tumor metastasis. Our goal is to accumulate additional clinical data regarding immune cell response to administrations of entolimod in order to guide future oncology development."

About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com .

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that do not relate strictly to historical or current facts. Words and phrases such as "potential," "may," "future," "will," "plan," "anticipate," "believe," "intend" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the company's future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals or the impact of any laws or regulations applicable to the company, and plans and objectives of management for future operations. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. 

These factors include, among others, the risks inherent in the early stages of drug development and in conducting clinical trials; the company's plans and expectations with respect to future clinical trials and commercial scale-up activities; the company's ability to attract collaborators with development, regulatory and commercialization expertise and the financial risks related to those relationships; the company's ability to comply with its obligations under license agreements; the company's inability to obtain regulatory approval in a timely manner or at all; the commercialization of the company's product candidates, if approved; the company's plans to research, develop and commercialize its product candidates; future agreements with third parties in connection with the commercialization of any approved product; the size and growth potential of the markets for the company's product candidates, and its ability to serve those markets; the rate and degree of market acceptance of the company's product candidates; the company's history of operating losses and the potential for future losses, which may lead the company to not be able to continue as a going concern; regulatory developments in the United States and foreign countries; the performance of the company's third-party suppliers and manufacturers; and the success of competing therapies that are or may become available. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the company's periodic filings with the Securities and Exchange Commission.

Contacts: Cleveland BioLabs, Inc. Rachel Levine Vice President, Investor Relations T: 917-375-2935 E: rlevine@cbiolabs.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 34

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 118

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 0

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 34

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 74

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 39

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
A Hybrid Book Bets on Muscles, Myth, and Machines

Updated Category News Views 66

Few publishing pitches ask readers to carry a barbell into Tartarus, but A R Quigley is plainly not chasing the middle of the bookstore. Doctrina Machina Learning Machine, released by Palmetto Publishing in November 2026, welds together a strength-training guide and an underground military science-fiction war story. That is an odd little contraption, no use pretending...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 188

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 169

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading

Top 5 Most Recently Viewed Articles

Melissa Tapanes Llahues Takes Charge as BASF President

Updated Category News Views 200

Melissa Tapanes Llahues Installed as President of BASF Bercow Radell Fernandez Larkin & Tapanes Partner continues her leadership across the development sectors Melissa Tapanes Llahues, an esteemed land use attorney and civic leader, has been officially installed as President of the Builders Association of South Florida (BASF), a key player in the region's development...

Continue Reading
Petco's Q2 2025 Results: A Look at Performance and Projections

Updated Category News Views 217

Petco's Q2 2025 Financial Results Overview Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) has revealed its financial performance for the second quarter of 2025, showcasing various achievement metrics and prospects for the remainder of the fiscal year. With a commitment to ongoing improvement, Petco has raised its earnings outlook and emphasized a strong economic...

Continue Reading
Empowering Women in STEM: A Transformative Networking Opportunity

Updated Category News Views 309

Empowering Women in STEM: A Transformative Networking Opportunity On November 12, a groundbreaking event titled "Connecting Our Talents; Women in STEM" will take place, bringing together female STEM students from various educational institutions. This event aims to highlight emerging talents and connect them with industry professionals, creating an invaluable network for...

Continue Reading
Analyzing Market Sentiment for Simpson Manufacturing Co Inc.

Updated Category News Views 260

Understanding Market Sentiment for Simpson Manufacturing Co Inc Simpson Manufacturing Co Inc's (NYSE: SSD) short interest has experienced a notable increase, with reports indicating a surge of 6.31% since the latest update. Currently, approximately 1.10 million shares have been sold short, which accounts for about 3.37% of the total shares available for trading. This...

Continue Reading
Growth of Hemp-Based Foods Market: Insights and Trends

Updated Category News Views 104

The Hemp-Based Foods Market: A Growing Trend The hemp-based foods market is experiencing remarkable growth, with projections indicating it will hit $10.6 billion by 2033. This marks a significant increase from $5.4 billion in 2023, boasting a compound annual growth rate (CAGR) of 7.2%. This upward trend shows a clear shift in consumer preferences toward plant-based diets,...

Continue Reading